Telomeres are composed of TTAGGG repeats and associated proteins.1 In somatic cells, telomere repeats are lost with each cell division, eventually leading to genetic instability and cellular senescence.2 In previous studies, we and others described substantial and disease stage–specific telomere shortening in Philadelphia chromosome–positive (Ph+) peripheral blood (PB) leukocytes from patients with chronic myeloid leukemia (CML).3 4 

The selective tyrosine kinase inhibitor imatinib blocks phosphorylation of tyrosine residues by occupying the adenosine triphosphate (ATP) site of BCR-ABL.5 Clinical phase 2 studies in CML revealed that the drug is capable of inducing major cytogenetic remissions in 60% of chronic phase (CP) patients previously treated with interferon α6, and even in about 26% of patients in accelerated phase (AP)7 and in 15% in myeloid blast crisis (BC).8 

In the current study, we sought to determine whether age-adjusted telomere length in PB granulocytes (ΔTELgran) is correlated with response to treatment with imatinib.

A total of 517 samples from 206 patients in CP, AP, and BC before and up to 706 days after initiation of imatinib therapy (median, 144 days) were analyzed by fluorescence in situ hybridization and flow cytometry (flow-FISH), telomere fluorescence was expressed in molecular equivalents of soluble fluorochrome units (MESF).9 Age-adjusted telomere length decreased dependent on disease stage from samples derived from patients in CP (median, −1.1 kMESF; 25-75 percentile; −3.3 to 1.2 kMESF), AP (−1.6 kMESF; −3.9 to 1.3 kMESF), and BC (−1.8 kMESF; −3.7 to 0.5 kMESF). However, the degree of telomere shortening was substantially less than what we had observed in previous studies performed in the “pre-imatinib era” of CML treatment.3 Therefore, we investigated the correlation between the duration of imatinib treatment and telomere length in the PB. Telomere length in samples from start of treatment up to day 144 was significantly shorter (mean ± SE; −1.5 ± 0.3 kMESF) compared with samples from patients treated for more than 144 days (−0.8 ± 0.3 kMESF, P = .035).

In order to analyze whether the increase in telomere length observed during imatinib treatment was due to a shift from Ph+ to Ph cells in the PB of these patients, samples were grouped based on the degree of remission achieved either in the bone marrow (BM) measured by conventional cytogenetics (Figure 1A) or in the PB by quantitative reverse transcriptase–polymerase chain reaction (RT-PCR) (Figure 1B). Telomere length in samples from patients in major or complete cytogenetic remission (median, −0.3 kMESF; 25-75 percentile; −2.8 to 2.6 kMESF; n = 58) was found to be longer compared with samples from patients with minor (−1.4 kMESF; −3.4 to 1.2 kMESF; n = 44) or without cytogenetic response (−1.7 kMESF; −3.9 to 0.6 kMESF; n = 144, P < .05 for difference between major and no cytogenetic response; Figure 1A). When the samples were grouped according to molecular remission10 (Figure 1B), median telomere length in samples from patients in good molecular response condition (BCR-ABL/ABL ratio < 2%, 0.6 kMESF; −2.3 to 3.0 kMESF; n = 44) was not different from age-adjusted controls but differed significantly from samples obtained from patients with no molecular response (BCR-ABL/ABL ratio > 14%, −1.8 kMESF; −4.1 to 0.3 kMESF; n = 278,P < .05). Patients with intermediate molecular response (BCR-ABL/ABL ratio 2%-14%) showed an intermediate degree of telomere reduction (−0.9 kMESF; −3.2 to 2.1 kMESF; n = 49).

Fig. 1.

Age-adjusted telomere length in patients with CML.

(A) Cytogenetic remission in the BM and (B) molecular response in the PB by quantitative RT-PCR.

Fig. 1.

Age-adjusted telomere length in patients with CML.

(A) Cytogenetic remission in the BM and (B) molecular response in the PB by quantitative RT-PCR.

Close modal

In summary, our observations reflect a steadily increasing fraction of Ph cells (with normal or only slightly reduced telomere length) contributing to the peripheral blood cell pool in patients receiving imatinib treatment. Cytogenetic and molecular responses achieved during imatinib therapy are associated with a normalization of previously shortened telomere length arguing against a preexisting telomere length deficit in normal hematopoietic stem cells from patients with CML at the time of malignant transformation.

This study was supported by fortune project No 697-0-0 from the University of Tübingen, the Sonderforschungsbereich 510 (Teilprojekt A6) of the Deutsche Forschungsgemeinschaft as well as a grant from the Deutsche Krebshilfe (no. Br 70-2746) and by a grant from the German Ministry of Education and Research (BMBF), Kompetenznetz Akute und chronische Leukämien-01 GI9980/6.

One of the authors (H.G.) has declared a financial interest in a company whose product was studied in the present work.

1
Blackburn
EH
Structure and function of telomeres.
Nature.
350
1991
569
573
2
de Lange
T
Telomere dynamics and genome instability in human cancer.
Telomeres.
Blackburn
EH
Greider
C
1995
265
293
Cold Spring Harbor Laboratory Press
Plainview, NY
3
Brummendorf
TH
Holyoake
TL
Rufer
N
et al
Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry.
Blood.
95
2000
1883
1890
4
Boultwood
J
Peniket
A
Watkins
F
et al
Telomere length shortening in chronic myelogenous leukemia is associated with reduced time to accelerated phase.
Blood.
96
2000
358
361
5
Druker
BJ
Tamura
S
Buchdunger
E
et al
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.
Nat Med.
2
1996
561
566
6
Kantarjian
H
Sawyers
C
Hochhaus
A
et al
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
N Engl J Med.
346
2002
645
652
7
Talpaz
M
Silver
RT
Druker
BJ
et al
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.
Blood.
99
2002
1928
1937
8
Sawyers
CL
Hochhaus
A
Feldman
E
et al
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.
Blood.
99
2002
3530
3539
9
Rufer
N
Brummendorf
TH
Kolvraa
S
et al
Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood.
J Exp Med.
190
1999
157
167
10
Hochhaus
A
Lin
F
Reiter
A
et al
Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction.
Blood.
87
1996
1549
1555
Sign in via your Institution